Imunon (IMNN) CEO Stacy Lindborg gets 1,803-share stock grant in lieu of salary

Rhea-AI Filing Summary

Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc.’s President and CEO Stacy Lindborg received a grant of 1,803 shares of common stock on June 18, 2026 at $1.82 per share. The stock was granted in lieu of cash for a portion of base salary, so it is compensation rather than an open-market purchase. Following this grant, Lindborg directly holds 7,038 common shares. A separate entry shows 778 common shares held indirectly through a 401(k) plan, which reflects a holding record rather than a new transaction.

Insights

Equity compensation analyst

CEO received routine stock-based pay, not an open-market buy.

Stacy Lindborg, President and CEO of Imunon, Inc., received 1,803 shares of common stock at $1.82 per share as compensation in lieu of a portion of base salary. This is coded as a grant/award acquisition rather than a market transaction.

After the award, Lindborg directly holds 7,038 common shares, plus 778 shares held indirectly via a 401(k) plan as of the same date. Because this is salary replacement, not discretionary buying or selling, it is typically viewed as a routine compensation event with neutral signaling value for investors.

Insider Trade Summary

Net Buyer: 1,803 shares

Net Buy 2 txns

Insider Lindborg Stacy

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,803	$1.82	$3K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 7,038 shares (Direct); Common Stock — 778 shares (Indirect, By 401(k) Plan)

Footnotes (1)

1. F1. Stock granted in lieu of cash for portion of base salary

Key Figures

Stock grant shares: 1,803 shares Grant price: $1.82 per share Direct holdings after grant: 7,038 shares +1 more

4 metrics

Stock grant shares 1,803 shares Common stock granted June 18, 2026

Grant price $1.82 per share Value used for stock granted in lieu of salary

Direct holdings after grant 7,038 shares Common stock directly held by CEO after transaction

Indirect 401(k) holdings 778 shares Common stock held indirectly via 401(k) plan

Key Terms

Grant, award, or other acquisition, 401(k) Plan, indirect ownership, non-derivative, +1 more

5 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

401(k) Plan financial

"nature_of_ownership: By 401(k) Plan"

A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.

indirect ownership financial

"ownership_type: indirect"

non-derivative financial

"transaction_type: non-derivative"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What did Imunon (IMNN) CEO Stacy Lindborg report in this Form 4?

Stacy Lindborg reported receiving 1,803 shares of Imunon common stock as compensation. The shares were granted at $1.82 per share in lieu of a portion of base salary, increasing her directly held position to 7,038 shares as of the transaction date.

Was the Imunon (IMNN) CEO’s Form 4 an open-market stock purchase?

No, the Form 4 shows a stock grant, not an open-market purchase. Stacy Lindborg received 1,803 common shares at $1.82 per share as equity compensation in place of part of her cash salary, which is classified as a grant/award acquisition.

How many Imunon (IMNN) shares does CEO Stacy Lindborg hold after this grant?

After the June 18, 2026 grant, Stacy Lindborg directly holds 7,038 Imunon common shares. In addition, a separate holding entry lists 778 common shares held indirectly through a 401(k) plan, reflecting retirement-plan ownership associated with her position.

What price was used for the Imunon (IMNN) stock granted to the CEO?

The 1,803 Imunon common shares granted to CEO Stacy Lindborg were valued at $1.82 per share. This price is used to record the equity compensation that replaced a portion of her base salary, rather than representing an open-market trading price decision.

How should investors view this Imunon (IMNN) Form 4 transaction?

This Form 4 reflects routine equity compensation, not a discretionary trade. The 1,803 shares granted at $1.82 per share replaced part of Stacy Lindborg’s cash salary. Such grants typically carry neutral signaling value, mainly showing the company’s use of stock-based pay.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 04:18 PM Accepted by SEC EDGAR 06/23/2026 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lindborg Stacy

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		A		1,803(1)	A	$1.82	7,038	D
Common Stock								778	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for portion of base salary

	/s/ Susan Eylward, Attorney-in-Fact for Stacy Lindborg	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)